azd5462
Small moleculeexperimental
Clinical trial activity
7 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
6
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Jul 27, 2021 (NCT04994106)
Timeline
Indications
Mechanism of action
- Relaxin receptor 1AGONIST
RXFP1 agonist
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06989983 | Phase 1 | May 20, 2025 | AstraZeneca, Quotient |
| NCT06661733 | Phase 1 | Nov 13, 2024 | AstraZeneca |
| NCT06639087 | Phase 1 | Sep 27, 2024 | AstraZeneca, Parexel |
| NCT06299826 | Phase 2 | Jun 4, 2024 | AstraZeneca |
| NCT05512806 | Phase 1 | Aug 24, 2022 | AstraZeneca, Parexel |
| NCT05395117 | Phase 1 | Jun 30, 2022 | AstraZeneca, Parexel |
| NCT04994106 | Phase 1 | Jul 27, 2021 | AstraZeneca |
Showing 7 of 7 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| AstraZeneca | For profit | 7 | 7 | 2 | 2021 |
| Parexel | For profit | 3 | 0 | 1 | 2022 |
| Quotient | For profit | 1 | 0 | 1 | 2025 |
3 organizations
Page 1 / 1